Stephan Bart

937 citations

19 papers · 438 indexed · 1 hit paper · h-index 11

Impact in

Infectious Diseases top 10%
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
Epidemiology top 10%
- Respiratory viral infections research
- Influenza Virus Research Studies
- Pneumonia and Respiratory Infections

Papers in ⓘ

Infectious Diseases 12
- Viral Infections and Outbreaks Research 6
- Viral gastroenteritis research and epidemiology 5
- Viral Infections and Vectors 4
- SARS-CoV-2 and COVID-19 Research 2
Epidemiology 12
- Respiratory viral infections research 7
- Influenza Virus Research Studies 4

Co-authors: Niranjan Kanesa-thasan (1 shared paper)Vas Narasimhan (1 shared paper)Philip R. Dormitzer (1 shared paper)Giovanni Della Cioppa (1 shared paper)Matthew Hohenboken (1 shared paper)Macaya Douoguih (7 shared papers)Benoît Callendret (7 shared papers)Esther Heijnen (4 shared papers)
Journals: Open Forum Infectious Diseases (3 papers)Vaccine (2 papers)The Journal of Infectious Diseases (2 papers)Human Vaccines & Immunotherapeutics (1 paper)International Journal of Infectious Diseases (1 paper)
Partner nations: United States Netherlands Belgium

In The Last Decade

Stephan Bart

19 papers receiving 423 citations

Hit Papers

align trajectories log scale

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults 2023 · 90 citations

Peers

Countries citing papers authored by Stephan Bart

Since Specialization

Citations

This map shows the geographic impact of Stephan Bart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Bart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Bart more than expected).

Fields of papers citing papers by Stephan Bart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Bart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Bart. The network helps show where Stephan Bart may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephan Bart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephan Bart Line = papers co-authored together Stephan Bart links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults New England Journal of Medicine ·Ann R. Falsey, Kristi L. Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K. H. Chan, Jerald Sadoff, Macaya Douoguih, Benoît Callendret, Christy Comeaux, Esther Heijnen Hit paper breakdown →	2023	90
2	A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults Science Translational Medicine ·Stephan Bart, Matthew Hohenboken, Giovanni Della Cioppa, Vas Narasimhan, Philip R. Dormitzer, Niranjan Kanesa-thasan	2014	78
3	A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant Vaccine ·Judith Falloon, Fei Ji, Craig Curtis, Stephan Bart, Eric Sheldon, Diane Krieger, Filip Dubovsky, Stacie Lambert, Therese Takas, Tonya Villafana, Mark T. Esser	2016	50
4	Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study Human Vaccines & Immunotherapeutics ·Stephan Bart, Kevin Cannon, Darrell T. Herrington, Richard Mills, Eduardo Forleo‐Neto, Kelly Lindert, Ahmed Abdul Mateen	2016	39
5	Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial International Journal of Infectious Diseases ·Christine A. Shaw, Lori Panther, Allison August, Tal Zaks, Igor Smolenov, Stephan Bart, Michael Watson	2019	26
6	Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study The Journal of Infectious Diseases ·Neil Goldstein, Viki Bockstal, Stephan Bart, Kerstin Lühn, Cynthia Robinson, Auguste Gaddah, Benoît Callendret, Macaya Douoguih	2020	24
7	A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults Vaccine ·Christine A. Shaw, Allison August, Stephan Bart, Peta-Gay Jackson Booth, Conor Knightly, Trevor Brasel, Scott C. Weaver, Haiyu Zhou, Lori Panther	2023	23
8	First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study PLoS ONE ·Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah, Dickson Anumenden, Jeroen N. Stoop, Anne Marit de Groot, Maria Grazia Pau, Jenny Hendriks, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Benoît Callendret, Kerstin Lühn, Macaya Douoguih, Cynthia Robinson	2022	19
9	Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study Contraception ·Stephan Bart, Joachim Marr, Konstanze Diefenbach, Dietmar Trummer, Carole Sampson-Landers	2011	17
10	Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study The Journal of Infectious Diseases ·Christy Comeaux, Stephan Bart, Arangassery Rosemary Bastian, Vladislav Klyashtornyy, Els De Paepe, Edmund Omoruyi, Leslie van der Fits, Roy van Heesbeen, Esther Heijnen, Benoît Callendret, Jerald Sadoff	2023	15
11	Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial Vaccines ·Sybil Tasker, Anna Wight O’Rourke, Anvar Suyundikov, Peta-Gay Jackson Booth, Stephan Bart, Vyjayanthi Krishnan, Jianfeng Zhang, Katie Anderson, Bertrand Georges, M. Scot Roberts	2021	15
12	LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study Open Forum Infectious Diseases ·Ann R. Falsey, Kristi L. Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, H. D. Boer, Sjoukje Vandenberghe, Eric K. H. Chan, Jerald Sadoff, Macaya Douoguih, Benoît Callendret, Christy Comeaux, Esther Heijnen	2021	10
13	Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study Health and Quality of Life Outcomes ·Baudouin Standaert, T. Dort, Janine Linden, Anuradha Madan, Stephan Bart, Laurence Chu, Mary S. Hayney, Mark Kosinski, Robin Kroll, Joel D. Malak, Genevieve Meier, Nathan Segall, Anne Schuind	2019	8
14	Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen npj Vaccines ·Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Lühn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih	2021	8
15	A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever PLoS neglected tropical diseases ·Robert T. Cartee, Ann Thanawastien, Thomas J. Griffin, John J. Mekalanos, Stephan Bart, Kevin Killeen	2020	5
16	Impact of smoked cannabis on tobacco cigarette smoking intensity and subjective effects: A placebo-controlled, double-blind, within-subjects human laboratory study. Experimental and Clinical Psychopharmacology ·Erica N. Peters, Evan S. Herrmann, Carson Smith, Jess Wilhelm, Bartosz Koszowski, Matthew S. Halquist, Leon Kośmider, Justin L. Poklis, Sage Roth, Stephan Bart, Wallace B. Pickworth	2020	4
17	2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine Open Forum Infectious Diseases ·Sybil Tasker, Vyjayanthi Krishnan, Stephan Bart, Anvar Suyundikov, Peta-Gay Jackson Booth, Anna Wight O’Rourke, Jianfeng Zhang, Bertrand Georges, Scot Roberts	2018	4
18	2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level Open Forum Infectious Diseases ·Christy Comeaux, Ann R. Falsey, Kristi Williams, Stephan Bart, John Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K. H. Chan, Jerald Sadoff, Macaya Douoguih, Benoît Callendret, Esther Heijnen	2022	2
19	Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults Journal of Virus Eradication ·Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Lühn, Wilbert van Duijnhoven, Carla Truyers, Benoît Callendret	2016	1

About Stephan Bart

Stephan Bart is a scholar working on Infectious Diseases, Epidemiology, Immunology, Emergency Medical Services and Health, having authored 19 papers that have together received 438 indexed citations. Recurring topics across this work include Respiratory viral infections research (7 papers), Viral Infections and Outbreaks Research (6 papers), Viral gastroenteritis research and epidemiology (5 papers), Influenza Virus Research Studies (4 papers), Viral Infections and Vectors (4 papers), Virus-based gene therapy research (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Immune Response and Inflammation (2 papers). The work is most often cited by research in Infectious Diseases (222 citations), Epidemiology (303 citations), Health (31 citations), Immunology (69 citations) and Agronomy and Crop Science (32 citations). Stephan Bart has collaborated with scholars based in United States, Netherlands and Belgium. Frequent co-authors include Niranjan Kanesa-thasan, Vas Narasimhan, Philip R. Dormitzer, Giovanni Della Cioppa, Matthew Hohenboken, Macaya Douoguih, Benoît Callendret, Esther Heijnen, Christy Comeaux and Jerald Sadoff. Their work appears in journals such as Open Forum Infectious Diseases, Vaccine, The Journal of Infectious Diseases, Human Vaccines & Immunotherapeutics and International Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact